Share Name Share Symbol Market Type Share ISIN Share Description
Yourgene Health Plc LSE:YGEN London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 11.38 539,636 08:00:00
Bid Price Offer Price High Price Low Price Open Price
11.25 11.50 11.38 11.38 11.38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.88 3.39 1.00 11.4 68.0
Last Trade Time Trade Type Trade Size Trade Price Currency
16:24:43 O 75,000 11.25 GBX

Yourgene Health (YGEN) Latest News

More Yourgene Health News
Yourgene Health Takeover Rumours

Yourgene Health (YGEN) Share Charts

1 Year Yourgene Health Chart

1 Year Yourgene Health Chart

1 Month Yourgene Health Chart

1 Month Yourgene Health Chart

Intraday Yourgene Health Chart

Intraday Yourgene Health Chart

Yourgene Health (YGEN) Discussions and Chat

Yourgene Health Forums and Chat

Date Time Title Posts
12/7/201921:35YourGene to Infinity726
29/4/201909:47Yourgene Health at the UK Investor Show-

Add a New Thread

Yourgene Health (YGEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-07-16 15:24:4411.2575,0008,437.50O
2019-07-16 15:22:5411.3711,0001,250.59O
2019-07-16 15:19:3311.3775,0008,527.50O
2019-07-16 14:41:0411.3050,0005,650.00O
2019-07-16 14:41:0011.3050,0005,650.00O
View all Yourgene Health trades in real-time

Yourgene Health (YGEN) Top Chat Posts

DateSubject
16/7/2019
09:20
Yourgene Health Daily Update: Yourgene Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker YGEN. The last closing price for Yourgene Health was 11.38p.
Yourgene Health Plc has a 4 week average price of 11.13p and a 12 week average price of 10.75p.
The 1 year high share price is 15.75p while the 1 year low share price is currently 6.50p.
There are currently 598,999,688 shares in issue and the average daily traded volume is 2,692,406 shares. The market capitalisation of Yourgene Health Plc is £68,136,214.51.
10/7/2019
09:39
swiftnick: So the combined business is still EBITDA negative.Yourgene -£3.1mElucigene + £1.0mSynergy cost savings from merger +£0.5mNet -£1.6mNot surprised to see the share price marked down. A lot of work still to do.
09/7/2019
13:25
twix386: That would be good Jonnycj. Too many times (every time to date) we have expected the latest expectations/news will not disappoint in share price terms like the previous ones have. Real quantifiable news. Material contracts with numbers. Not attending conferences, dilution and no contract news for over a year! Could this be the time? It would be about time!!! We have made good progress under new ceo and tomorrow's rns should underpin our progress and prospects. The future looks the best it's ever been. I hope we can deliver shareholder value (a re-rate) before the next funding!
09/7/2019
13:14
jonnycj: Comprehensive, fully informed broker note with sensible TP would be my guess and share price will trend towards it. Bear in mind it’s now a multi faceted business, so lots of revenue streams to forecast. Exciting times ahead !
09/7/2019
12:53
twix386: Yup, I think likewise - No re-rate on the cards STILL for tomorrow's rns, but could see a spike or rise over a few days before falling back. My hope would be that after results and broker note a material contract rns (with figures) will propel us into some sort of re-rate when all added together - well 15p+ anyway. MUST be about time we secured a material contract or one deemed worthy of letting us know about!! This share has been terminally disappointing in terms of share price.
09/7/2019
11:11
twix386: Straw poll....After tomorrow's rns do we think for the first time the share price is going to react by gradually and sustainably rising?It's not happened on prior hopes, but who knows we could even see the re-rate finally take hold. Usual anti-climax or long awaited re-rate?
25/6/2019
10:09
twix386: The usual share price move after news is conference attendance.
09/6/2019
11:12
twix386: A question.Today TW has stated...."Today we run details of a chat with Adam Reynolds at Yourgene about why he has just bought so many shares and why the share price could rocket by almost 50% in short order."What is TW's current revised stated price target?Wasn't it iro 20p? Down from past targets after delays and dilution.So, with today's almost 50% hope that would reveal iro 15p!!! Ticketing half the price target I had him set at??
19/4/2019
19:11
scotty1: Another good reasoned post from notaflipper over the road. Obviously there's a lot of information to take in so let's go through the deal the circa 20% share expansion and TW's valuation. If I am honest TW's reaction seems very stage managed. Having known the Trading Statement date he was probably aware hence making this his 'nap' tick for end of April. Otherwise him, and other backroom commentators, expectations of a spike would have optimistically been based on the TS alone. Elucigene has launched 36 commercial products. Its main product categories cover Cystic Fibrosis Kits, Rapid Aneuploidy Analysis, Reproductive Health, Genetic Disease Diagnosis. The business was founded 20 years ago by pharmaceutical giant AstraZeneca and has changed hands several times since. In October 2013 the business was established as an independent company, when Scott Higgins, 55, and Mike Webb, 60, led a management buyout backed by Percipient Capital.Gross. Elucigene had a turnover of £3.6m in FY2018 with a with a cost of sales of £500k. This means a Cash Generative business already of surplus £3.1m. Cash is £1.3m, gross and operating profits £0.6 million and net cash is £0.4 million . The company plans to expand internationally and sees South America and India as key markets for its growth. More importantly for YGEN holders it plans to expand into the US this year https://www.elucigene.com/elucigene-targets-us-for-next-stage-of-export-drive/ The Enlarged company though it will have 574,418,577 shares after and potentially a further 11,550,000 if TMO further subscribe will have also the following: Elucigene's product offering plus IONA test plus further product expansions - no long overdue to be announced - such as pre-implantation genetic screening (PGS), Rhesus disease screens, BRAC1 screen and Illumina's version of the IONA test. In total the product portfolio now will be close to 40. The Enlarged company would have sales of £12.5 million in FY2018. Elucigene have no public sales forecasts so even if we assume they're flat at £3.6m the Enlarged Company will have improved sales forecasts of £16.1M in FY2020E and £20.8M in FY2021E. Break-even to be achieved this year. On a fully diluted basis of 586m shares at 17p share price the market capitalisation would be £99.6m. With currently 459m at a proposed share price of 20p the market capitalisation would be £91.8m. TW HAS UPGRADED HIS VALUATION. To be fair to TW the reason his share price targets fail is there's not been much volume. Much of the share price movement has been driven by Steve Myers. With swing traders making up 2/3p movement. Hence the tedious trading pattern between 13.5 to 10.5p since February. On Friday we saw 6m shares traded this bodes well in addition to new investors and a 12 month lock-in period for new shares. Even at 17p this would be very low. With sales of £16m in FY2020E the current share price on a fully diluted basis is £70m. This gives a 4.5 EV/sales multiple of 4.4. At 17p an EV of £99m would be 6. Considering the test volumes will now be in excess of 100k an EV/sales multiple closer to 10x would be fairer. These figures are also conservative because we do not know Elucigene's sales forecasts or the new test volumes expected by new products this year. I suspected that the TW's mood will be come better in the next week or so with a revised broker rating and research note which may be accompanied by further potentially further announcements. Thereafter a stage managed increase in target will predictably ensue.
17/4/2019
23:53
ngen yap: What a surprising but good news! An astute and strategically fit acquisition. It explains the share price action (or inaction) since trading update, and mooted recent investor roadshow. I won't dwell into why I think this is a superb acquisition, the directors summarised it very well in the rationale section of RNS. Worth a few read. I will confess to not fully understanding the science behind our business but I do think the numbers are much easier to forecast, given the base we have built and relatively predictable model. I have shared below my expectations for YE19, YE20 and YE21. Pleased to say that the recent trading update validated my YE19 expectations. Who needs Finncapp and Hardman eh?! Today's news accelerated my target share price of 50p to within 2 years. My expectations for YE20 is now revenue of circa £18m with OP of £2m, and for YE21 revenue to reach £30m with OP of £7m. It's no wonder that Bill Chang, a significant shareholder already and founder of Yourgene, continues to plough significant investment into his holdings. Lynn Rees meanwhile might not have subscribed as much, hold significant options at 10p and 10.25p. Not dissimilar in my view other than timing of investment. People spoke about futher dilution by Thermo. Yes, new shares but don't forget they have to pay for them. If they do invest, I see that as a strong signal. Being in bed with 2 of the world leading platform, an expanded geographic footprint (just doubled), expanding product portfolio, growth will be significant. So happy to be invested. Will continue to hold and add as and when I can. Good luck all.
16/4/2019
15:43
scotty1: A bit of light reading getting a value on YGEN using the Discounted Cash Flow method,there are other methods obviously and personally i think their valuation is a bit on the cautious side,but that's just my opinion,another rider is they obviously don't take into account any news on new products that are expected at some point. Is There An Opportunity With Yourgene Health Plc’s (LON:YGEN) 38% Undervaluation? Simply Wall St April 16, 2019 The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is £82.63m. To get the intrinsic value per share, we divide this by the total number of shares outstanding. This results in an intrinsic value estimate of £0.18. Relative to the current share price of £0.11, the company appears quite undervalued at a 38% discount to what it is available for right now. Remember though, that this is just an approximate valuation, and like any complex formula – garbage in, garbage out. https://simplywall.st/stocks/gb/healthcare/aim-ygen/yourgene-health-shares/news/is-there-an-opportunity-with-yourgene-health-plcs-lonygen-38-undervaluation/
Yourgene Health share price data is direct from the London Stock Exchange
Your Recent History
LSE
YGEN
Yourgene H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190717 05:15:44